What question did this study set out to answer?

This research explores the role of DOCK4 as a prognostic biomarker in clear cell renal cell carcinoma (ccRCC).

March 15, 2026Annals of Medicine0 citationsOpen Access

Elevated DOCK4 expression correlates with favorable prognosis and immune infiltration in clear cell renal cell carcinoma

DHDa-Long HeJining Medical University FZFangfang ZhuShandong Provincial Hospital JWJ Y WangAffiliated Hospital of Jining Medical University

Key Points

This research explores the role of DOCK4 as a prognostic biomarker in clear cell renal cell carcinoma (ccRCC).
Analyzed DOCK4 expression levels in ccRCC samples
Evaluated correlation between DOCK4 expression and pathologic staging
Examined impact on survival rates
Investigated the role of DOCK4 in tumor immune microenvironment (TIME)
High DOCK4 expression correlates with favorable pathologic staging
Patients with elevated DOCK4 have improved survival
DOCK4 may serve as a therapeutic target for immunotherapy in ccRCC

Abstract

DOCK4 is a promising prognostic biomarker in ccRCC, with high expression indicating favorable pathologic staging and improved survival. Its role in modulating the TIME suggests that DOCK4 could also serve as a therapeutic target, potentially guiding future immunotherapy strategies for this aggressive malignancy.

Demander à l'IA

Bookmark

View Full Paper